Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate
AU-011 is a virus-like drug conjugate derived from the human papillomavirus. It is the company’s first investigational virus-like drug conjugate. There are currently no approved targeted therapies for non-muscle invasive bladder cancer.
The company plans on investigating the drug in this indication through a phase 1 clinical trial that is expected to begin later this year.
Aura Biosciences is a biopharmaceutical company aiming to transform the treatment of early-stage tumours to prevent metastasis and improve outcomes for patients with cancer. Aura Biosciences is developing a new class of therapies to selectively target and destroy cancer cells, while leaving surrounding tissue unharmed. Founded: 2009, Headquarters: Cambridge, Massachusetts, United States.
August 12, 2022